Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint

Spectrum Pharmaceutical (SPPI) - Get Report lost more than half its market value Thursday after the biopharma reported that a Phase II trial for a drug designed to treat the most common form of lung cancer had not met its primary endpoint.